Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Psyence Biomedical ( (PBM) ) has issued an announcement.
On August 28, 2025, Psyence Biomedical announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The event will allow the company to engage with global investors and present its business strategy and pipeline, emphasizing its unique approach in psychedelic medicine and its operational footprint in Africa. The company will also host a webinar for investors on September 16, 2025, to discuss its clinical development programs and strategic initiatives, further solidifying its position in the psychedelic medicine sector.
More about Psyence Biomedical
Psyence Biomedical Ltd. is a biopharmaceutical company specializing in psychedelic-based therapeutics, focusing on nature-derived psilocybin and ibogaine therapies for mental health needs. It is a vertically integrated company and the first of its kind listed on Nasdaq, dedicated to addressing unmet mental health needs, particularly in palliative care.
Average Trading Volume: 1,650,515
Technical Sentiment Signal: Sell
Current Market Cap: $2.28M
For detailed information about PBM stock, go to TipRanks’ Stock Analysis page.